{"disease":{"id":"pancreatic-neuroendocrine-tumors","name":"pancreatic neuroendocrine tumors"},"drugs":{"marketed":[{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumors (pNET)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04282083","title":"Protocol ITANET - Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Italian Association Neuroendocrine Tumors","has_results":false},{"nct_id":"NCT04074135","title":"Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02630654","title":"Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs","phase":"","overall_status":"COMPLETED","enrollment_count":404,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT07165886","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":243,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT07274657","title":"Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"GCS Ramsay Santé pour l'Enseignement et la Recherche","has_results":false},{"nct_id":"NCT02730104","title":"Community-based Neuroendocrine Tumor (NET) Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT02282059","title":"The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04476082","title":"Nutrition in Gastrointestinal Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"University Medicine Greifswald","has_results":false},{"nct_id":"NCT02842749","title":"Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04086485","title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07536087","title":"Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Institute for Clinical and Experimental Medicine","has_results":false},{"nct_id":"NCT07121478","title":"Patients With High-grade Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":46,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT04524442","title":"Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true},{"nct_id":"NCT05411133","title":"Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Arbele Pty Ltd","has_results":false},{"nct_id":"NCT03043664","title":"Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT05243082","title":"Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06937112","title":"18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT02608203","title":"[68 Ga]-DOTANOC PET/CT in GEP-NETs","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT04077372","title":"Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers","phase":"NA","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT04711135","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true},{"nct_id":"NCT04644315","title":"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04614766","title":"A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"David Bushnell","has_results":false},{"nct_id":"NCT01980732","title":"68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Andrei Iagaru","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}